Abeona Therapeutics receives FDA Fast Track designation for its ABO-101 gene therapy

Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company co-headquartered in Cleveland and New York, has received a boost from federal regulators with respect to development of a therapy for a metabolic disorder.

The company announced in a news release on Thursday, April 4, that the U.S. Food and Drug Administration has granted Fast Track designation to ABO-101, which is Abeona’s one-time gene therapy for Sanfilippo syndrome type B, or MPS IIIB.

Click here to read the complete article.

Story excerpt provided by Crain’s Cleveland Business.

Originally published April 4, 2019.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: